Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A 'Stranger Things' documentary covering the final season is on its way: Watch the trailer - 2Vote In favor of Your Favored Kind Of Tea
- 3Launch pad damaged as Russian rocket blasts off for space station, agency says
- 4Hamas Navy head, engineer of Khan Yunis tunnel network killed in Gaza, IDF confirms
- 5As reefs vanish, assisted coral fertilization offers hope in the Dominican Republic
- A few Exemplary Chinese Dishes, Which Are Famous Around the world
- 'The Housemaid' movie with Sydney Sweeney and Amanda Seyfried premieres this month. What the stars have said about the psychological thriller.
- NASA study shows how satellite 'light pollution' hinders space telescopes
- Step by step instructions to Guarantee Your Lab Precious stone is Morally Obtained
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- Travels to Dream Objections in Europe
- Avoid Slam: Exploring the Pickup Truck Transformation
- Parents who delay baby's first vaccines also likely to skip measles shots
- ChatGPT served as "suicide coach" in man's death, lawsuit alleges
